ArticleAnnals of medicine and surgery (2012)2025
The beneficial effects of bevacizumab on the progression of non-arteritic anterior ischemic optic neuropathy: a case-control study.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline retinal nerve fiber layer thickness as a predictive biomarker for endoscopic optic canal decompression in NAION: towards a precision medicine approach.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study was designed to explore the effect of intravitreal bevacizumab injection on the progression of non-arteritic anterior ischemic optic neuropathy (NAION) patients, offering a ray of hope in treating this condition. Materials and methods: The current investigation was a case-control study in which the demographic records of patients diagnosed with NAION. The total included 30 patients, divided into two main groups: the treatment group, which received intravitreal bevacizumab administration (n = 15), and the control group (n = 15), which was treated without bevacizumab. Bevacizumab (1.25 mg) was injected into the eye through a transscleral approach using a 25-gauge needle. Tetracaine, lidocaine, and gatifloxacin drops were applied for anesthesia and post-treatment. Visual acuity was measured using letter scores at a distance of 2 meters. Visual fields and optic nerve imaging were used to assess retinal nerve fiber layer (RNFL) thickness. Results: Eye involvement was evenly distributed between the right and left eyes. A two-way ANOVA revealed a significant difference in RNFL thickness between injection groups (F(2, 28) = 3.985, Conclusion: The data obtained from this study suggest that intravitreal bevacizumab administration may offer promising effects on the progression of NAION patients, providing a reassuring and confident outlook for the future of NAION treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.